^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    APR-548

    i
    Other names: APR-548, APR-246 analog, MQ Prodrug
    Company:
    Aprea
    Drug class:
    p53 reactivator
    Related drugs:
    over2years
    APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) (clinicaltrials.gov)
    P1, N=4, Terminated, Aprea Therapeutics | N=46 --> 4 | Suspended --> Terminated; Sponsor decision
    Enrollment change • Trial termination • Combination therapy
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    azacitidine • APR-548
    over2years
    APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) (clinicaltrials.gov)
    P1, N=46, Suspended, Aprea Therapeutics | Recruiting --> Suspended
    Trial suspension • Combination therapy
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    azacitidine • APR-548
    almost3years
    APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) (clinicaltrials.gov)
    P1, N=46, Recruiting, Aprea Therapeutics | Trial primary completion date: Dec 2021 --> Apr 2022
    Clinical • Trial primary completion date • Combination therapy
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    azacitidine • APR-548
    3years
    APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) (clinicaltrials.gov)
    P1, N=46, Recruiting, Aprea Therapeutics | Initiation date: Apr 2021 --> Sep 2021
    Clinical • Trial initiation date • Combination therapy
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    azacitidine • APR-548
    over3years
    APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) (clinicaltrials.gov)
    P1, N=46, Recruiting, Aprea Therapeutics | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    azacitidine • APR-548
    4years
    APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) (clinicaltrials.gov)
    P1, N=46, Not yet recruiting, Aprea Therapeutics
    Clinical • New P1 trial • Combination therapy
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    azacitidine • APR-548